Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.

Paul G. Richardson,Sagar Lonial,Robert Schlossman,Anuja Roy,Istvan Majer,Ashok Panneerselvam,Monika Sopala,Jesús F. San Miguel

Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.

2016

Paul G. Richardson
Sagar Lonial
Robert Schlossman
Anuja Roy
Istvan Majer
Ashok Panneerselvam
Monika Sopala
Jesús F. San Miguel

8054Background: PAN, in combination with bortezomib (BTZ) and dexamethasone (DEX), is FDA-approved for the treatment of MM patients who have received ≥ 2 prior regimens, including BTZ and an immuno...

Keywords:

Placebo
Physical therapy
Panobinostat
Multiple myeloma
Medicine
Dexamethasone
Bortezomib
Oncology
Internal medicine
double blind
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations